Our Transactions
Leadership across the largest and most complex situations
Lead Financial Advisor
on its pending €8.0 billion
acquisition of
from Vodafone Group
2024
Exclusive Financial Advisor
on its pending ~$2.3 billion
acquisition of
2024
Independent Financial Advisor
on its pending acquisition of three fill-finish sites for an upfront payment of $11 billion from Novo Holdings following its $16.5 billion acquisition of Catalent
2024
Exclusive Financial Advisor
on its pending ~$35 billion
acquisition of
2024
Exclusive Financial Advisor
on its pending ~$12.6 billion
sale to
2024
Lead Financial Advisor
on its pending $11.5 billion
all-stock merger with
2024
Lead Financial Advisor
on its pending ~$13.4 billion
sale to
2023
Financial Advisor
on its pending ~$14.9 billion
sale to
2023
Financial Advisor
on its pending $60 billion
all-stock acquisition of
2023
Financial Advisor
on its up to $5.8 billion
acquisition of
2023
Financial Advisor
on its pending ~$20 billion
merger with
2023
Lead Left Bookrunner
$300 million
Follow-on Offering
2023
Exclusive Financial Advisor
on its chapter 11 restructuring of ~$1.9 billion of debt and $125 million DIP ABL financing
2023
Active Bookrunner
$1.1 billion IPO & $1.6 billion
Follow-on Offering
2023
Exclusive Financial Advisor
on its pre-packaged chapter 11 restructuring of ~$3.6 billion of debt and preferred equity
2023
Lead Financial Advisor
on its ~$36 billion
spin-off of
2021
Anouncement Date1
Status
Transaction
Value (M)
January 8, 2024
Closed
Advised Merck on its acquisition of Harpoon Therapeutics
~$680
January 8, 2024
Pending
Advising an Ad Hoc Group of 2L Noteholders on Audacy’s Prepackaged Chapter 11 Restructuring
~$1,900
1Announcement date for M&A transactions represents the date publicly announced; announcement date for restructurings represents the date publicly announced or filed; announcement date for capital markets transactions represents the pricing date.
« Previous 1 … 7 8 9